ВАК (Россия)
РИНЦ (Россия)
EBSCO
Регистрационное агентство DOI (США)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

НЕАЛКОГОЛЬНАЯ ЖИРОВАЯ БОЛЕЗНЬ ПЕЧЕНИ: ПРИНЦИПЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯ

Скачать статью в PDF
Номер журнала: 
7
Год издания: 
2017

А. Свистунов, член-корреспондент РАН, доктор медицинских наук, профессор, М.А. Осадчук, доктор медицинских наук, профессор, Д. Балашов, кандидат медицинских наук, М.М. Осадчук, кандидат медицинских наук Первый МГМУ им. И.М. Сеченова (Сеченовский Университет) E-mail: osadchuk.mikhail@yandex.ru

Продемонстрированы основные этиологические и патогенетические механизмы развития неалкогольной жировой болезни печени. Особое внимание уделено тактике ведения подобных больных, исходя из рекомендаций Американской коллегии гастроэнтерологов, Американской гастроэнтерологической ассоциации, Американской ассоциации по изучению болезней печени, Европейской ассоциации по изучению болезней печени, Европейской ассоциации по изучению диабета, Европейской ассоциации по изучению ожирения, Российского общества по изучению печени и Российской гастроэнтерологической ассоциации.

Ключевые слова: 
гепатология
неалкогольная жировая болезнь печени
этиопатогенез
тактика ведения

Для цитирования
Свистунов А., Осадчук М.А., Балашов Д., Осадчук М.М. НЕАЛКОГОЛЬНАЯ ЖИРОВАЯ БОЛЕЗНЬ ПЕЧЕНИ: ПРИНЦИПЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯ . Врач, 2017; (7): 13-18


It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Gerss J., Kopcke W. The questionable association of vitamin E supplementation and mortality – inconsistent results of different meta-analytic approaches // Cell Mol. Biol. – 2009; 55 (Suppl. OL): 1111–20.
  2. Williams C., Stenger J., Asike M. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle -aged population utilizing ultrasound and liver biopsy: a prospective study // Gastroenterology. – 2011; 140: 124–31.
  3. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации // Рос. журн. гастроэнтерол., гепатол. и колопроктол. – 2016; 2: 24–42.
  4. Marchesini G., Bugianesi E., Forlani G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome // Hepatology. – 2003; 37: 917–23.
  5. Williams C., Stengel J., Asike M. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study // Gastroenterology. – 2011; 140: 124–31.
  6. McCullough A. Pathophysiology of nonalcoholic steatohepatitis // J. Clin. Gastroenterol. – 2006; 40 (Suppl. 1): 17–29.
  7. Charlton M., Burns J., Pedersen R. et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States // Gastroenterology. – 2011; 141: 1249–53.
  8. Milic S., Mikolasevic I., Krznaric-Zrnic I. et al. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options // Drug Des. Devel. Ther. – 2015; 9: 4835–45. DOI: 10.2147/DDDT.S64877.
  9. Arguello G., Balboa E., Arrese M. et al. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease // Biochim. Biophys. Acta. – 2015; 1852 (9): 1765–78. DOI: 10.1016/j.bbadis.2015.05.015.
  10. Chalasani N., Younossi Z., Lavine J. et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association // Am. J. Gastroenterol. – 2012; 107: 811–26.
  11. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease // Diabetologia. – 2016; 59 (6): 1121–40. DOI: 10.1007/s00125-016-3902-y.
  12. Takahashi Y., Sugimoto K., Inui H. et al. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis // World J. Gastroenterol. – 2015; 21 (13): 3777–85.
  13. Chan W., Nik Mustapha N., Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Non-alcoholic Steatohepatitis // Clin. Gastroenterol. Hepatol. – 2017; pii: S1542-3565(17)30459-7. DOI: 10.1016/j.cgh.2017.04.016.
  14. Le T., Loomba R. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis // J. Clin. Exp. Hepatol. – 2012; 2: 156–73.
  15. Promrat K., Kleiner D., Niemeier H. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis // Hepatology. – 2010; 51: 121–9.
  16. Ryan M., Itsiopoulos C., Thodis T. et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease // J. Hepatol. – 2013; 59: 138–43.
  17. Kastorini C., Milionis H., Esposito K. et al. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals // J. Am. Coll. Cardiol. – 2011; 57: 1299–313.
  18. Janczyk W., Socha P., Lebensztejn D. et al. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial // BMC Pediatr. – 2013; 13: 85.
  19. Malaguarnera M., Vacante M., Antic T. et al. Bifidobacteriumlongum with fructo-oligosaccharides in patients with nonalcoholic steatohepatitis // Dig. Dis. Sci. – 2012; 57: 545–53.
  20. Ratziu V., Giral P., Jacqueminet S. et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial // Gastroenterology. – 2008; 135: 100–10.
  21. Chalasani N., Younossi Z., Lavine J. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association // Hepatology. – 2012; 55: 2005–23.
  22. Lewis J., Ferrara A., Peng T. et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study // Diabetes Care. – 2011; 34: 916–22.
  23. Lomonaco R., Sunny N., Bril F. et al. Nonalcoholic fatty liver disease: current issues and novel treatment approaches // Drugs. – 2013; 73: 1–14.
  24. Haukeland J., Konopski Z., Eggesbø H. et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial // Scand. J. Gastroenterol. – 2009; 44: 853–60.
  25. Lavine J., Schwimmer J., Van Natta M. et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial // JAMA. – 2011; 305: 1659–68.
  26. Miller E., Pastor-Barriuso R., Dalal D. et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality // Ann. Intern. Med. – 2005; 142: 37–46.
  27. Klein E., Thompson I., Tangen C. et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) // JAMA. – 2011; 306: 1549–56.
  28. Dima A., Marinescu A., Dima A.C. Non-alcoholic fatty liver disease and the statins treatment // Rom J. Intern. Med. – 2012; 50: 19–25.
  29. Foster T., Budoff M., Saab S. et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial // Am. J. Gastroenterol. – 2011; 106: 71–7.
  30. Tomeno W., Yoneda M., Imajo K. et al. Emerging drugs for non-alcoholic steatohepatitis // Expert Opin. Emerg. Drugs. – 2013; 18: 279–90.
  31. Satapathy S., Sakhuja P., Malhotra V. et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis // J. Gastroenterol. Hepatol. – 2007; 22: 634–8.
  32. Van Wagner L., Koppe S., Brunt E. et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial // Ann. Hepatol. – 2011; 10: 277–86.
  33. Zein C., Yerian L., Gogate P. et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial // Hepatology. – 2011; 54: 1610–9.
  34. Lindor K., Kowdley K., Heathcote E. et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial // Hepatology. – 2004; 39: 770–8.
  35. Han Y., Shi J., Ma A. et al. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose // Clin. Drug Investig. – 2014; 34: 1–7.
  36. Neuschwander-Tetri B., Loomba R., Sanyal A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicenter, randomised, placebo-controlled trial // Lancet. – 2015; 385: 956–65.
  37. Georgescu E., Ionescu R., Niculescu M. et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis // World J. Gastroenterol. – 2009; 15: 942–54.
  38. Yokohama S., Yoneda M., Haneda M. et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis // Hepatology. – 2004; 40: 1222–5.
  39. Eslamparast T., Eghtesad S., Hekmatdoost A. et al. Probiotics and Nonalcoholic Fatty liver Disease // Middle East J. Dig. Dis. – 2013; 5: 129–36.
  40. Li Z., Yang S., Lin H. et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease // Hepatology. – 2003; 37: 343–50.
  41. Vajro P., Mandato C., Licenziati M. et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease // J. Pediatr. Gastroenterol. Nutr. – 2011; 52: 740–3.
  42. Küçükazman M., Ata N., Dal K. et al. The association of vitamin D deficiency with nonalcoholic fatty liver disease // Clinics (Sao Paulo). – 2014; 69: 542–6.
  43. Strange R., Shipman K., Ramachandran S. Metabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcome // World J. Diabetes. – 2015; 6: 896–911.
  44. Targher G., Bertolini L., Scala L. et al. Association between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease // Nutr. Metab. Cardiovasc. Dis. – 2007; 17: 517–24.
  45. Dasarathy J., Periyalwar P., Allampati S. et al. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease // Liver Int. – 2014; 34: 118–27.
  46. Al-Jassabi S., Saad A., Azirun M. et al. The role of Silymarin in prevention of Alloxan-induced diabetes mellitus in Balb/C mice // American-Eurasian J. Toxicol. Sci. – 2011; 3 (3): 172–6.
  47. Malihi F., Hosseini-Tabatabaei A., Esmaily H. et al. Improvement of inflammatory and toxic stress biomarkers by silymarin in a murine model of type one diabetes mellitus // Central Eur. J. Biol. – 2009; 4 (3): 369–80. DOI: 10.2478/s11535-009-0014-4.
  48. Liu J., Zhang M., Wang W. et al. Chinese herbal medicines for type 2 diabetes mellitus // Cochrane Database Syst. Rev. – 2004; 3: CD003642.
  49. Del Ben M., Polimeni L., Baratta F. et al. Modern approach to the clinical management of non-alcoholic fatty liver disease // World J. Gastroenterol. – 2014; 20: 8341–50.
  50. Loguercio C., Andreone P., Brisc C. et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial // Free Radic. Biol. Med. – 2012; 52: 1658–65.
  51. Caiazzo R., Lassailly G., Leteurtre E. et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study // Ann. Surg. – 2014; 260: 893–8.